Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Oncology

Survivorship, Monitoring Your Health & Risk Stratification

At a Glance

After primary treatment for soft tissue sarcoma, patients enter a surveillance phase to monitor for recurrence. Expect MRI scans of the original tumor site and chest CTs to check the lungs every 3 to 6 months initially. Doctors use statistical tools like the Sarculator to personalize this schedule.

Finishing primary treatment—surgery, radiation, or chemotherapy—is a major milestone. However, for many patients, this transition marks the beginning of a new kind of challenge: the “watchful waiting” phase. Because soft tissue sarcoma (STS) has a risk of returning, long-term monitoring (surveillance) is a standard part of your care [1][2].

The Standard Surveillance Schedule

The goal of surveillance is to catch any recurrence as early as possible, when it is most treatable [3]. Your schedule is typically “front-loaded,” meaning scans are more frequent in the first few years when the risk of recurrence is highest [1].

  • Years 1–3: You will likely have imaging every 3 to 6 months. For high-grade tumors, the frequency is usually closer to every 3 months [1][4].
  • Years 4–5: If everything remains clear, scans usually move to every 6 months [1].
  • Years 5–10: Monitoring often continues annually for up to ten years [2].

What Scans to Expect

  • Local Monitoring (The Original Site): MRI is the preferred tool for checking the area where your tumor was first removed [5]. It provides the most detailed view of soft tissue to help doctors distinguish between normal surgical scarring and a new growth [6].
  • Distant Monitoring (The Lungs): In adult soft tissue sarcoma, the lungs are the most common site for the cancer to spread (metastasize) [7][8]. For this reason, a chest CT is the standard monitoring tool, as it is much more sensitive than a standard chest X-ray at finding tiny “nodules” [5][9].

Understanding Your Risk: Nomograms

To help personalize your follow-up, your doctor may use a nomogram—a statistical tool that calculates your individual risk of recurrence based on factors like tumor size, depth, and FNCLCC grade [10].

Common tools include the Sarculator and PERSARC [11][12]. While these are helpful for setting expectations and deciding if you need more aggressive follow-up, they have limitations:

  • Subtype Differences: They may be less accurate for extremely rare subtypes [12].
  • General Estimates: A nomogram provides a mathematical probability based on thousands of other patients, but it cannot predict with 100% certainty what will happen in your specific body [13].

Navigating “Scanxiety”

It is completely normal to feel a spike in anxiety in the days or weeks leading up to your follow-up appointments—a phenomenon often called scanxiety [14]. This feeling is a valid response to the uncertainty of survivorship.

To help manage this, many patients find it useful to:

  1. Schedule Scans Early: Ask for the earliest appointment of the day to reduce the hours spent waiting.
  2. Request Results Quickly: Ask your doctor how and when results will be shared (e.g., via a patient portal or a phone call).
  3. Focus on the “Plan”: Remember that these scans are a tool for empowerment—they are the way your team ensures that if anything changes, you can act immediately [15][16].

While the “waiting” phase can feel passive, staying diligent with your appointments and engaging in ongoing physical therapy to maintain limb function are the most active things you can do to protect your health in the long term [1].

Common questions in this guide

How often will I need scans after soft tissue sarcoma treatment?
In the first 1 to 3 years after treatment, you will typically have scans every 3 to 6 months. This frequency usually decreases to every 6 months for years 4 and 5, and then annually up to year 10.
Why do I need a chest CT scan instead of a regular chest X-ray?
In adult soft tissue sarcoma, the lungs are the most common place for cancer to spread. A chest CT scan is used because it is much more sensitive than a standard X-ray for detecting tiny lung nodules early.
What type of scan is used to monitor my original tumor site?
An MRI is the preferred tool for checking the original surgical site. It provides detailed views of soft tissues, which helps your medical team distinguish normal surgical scarring from new tumor growth.
What is a nomogram like the Sarculator?
A nomogram, such as the Sarculator or PERSARC, is a statistical tool your doctor uses to estimate your individual risk of recurrence. It uses factors like your tumor's size, depth, and grade to help personalize your follow-up care plan.
How can I deal with scanxiety before my follow-up appointments?
Scanxiety is a completely normal response to the uncertainty of survivorship. To help manage it, try scheduling your scans early in the day, confirm how and when results will be shared, and remember that monitoring is an active tool to protect your health.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my tumor's grade and size, what is my specific surveillance schedule for the next three years?
  2. 2.Why are we using chest CT instead of X-rays for my lung monitoring?
  3. 3.Can you show me my 'Sarculator' or 'PERSARC' score and explain what its limitations are for my specific subtype?
  4. 4.What symptoms should I specifically be looking for at the original surgical site?
  5. 5.If a scan shows something suspicious, what is the process for a biopsy or follow-up?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Mapping the Course of Recovery Following Limb-Salvage Surgery for Soft-Tissue Sarcoma of the Extremities.

    Lazarides AL, Burke ZDC, Gundavda MK, et al.

    The Journal of bone and joint surgery. American volume 2024; (106(19)):1797-1808 doi:10.2106/JBJS.23.01007.

    PMID: 39172902
  2. 2

    Designing a Rational Follow-Up Schedule for Patients with Extremity Soft Tissue Sarcoma.

    Wilson DAJ, Gazendam A, Visgauss J, et al.

    Annals of surgical oncology 2020; (27(6)):2033-2041 doi:10.1245/s10434-020-08240-z.

    PMID: 32152780
  3. 3

    Local recurrence management of extremity soft tissue sarcoma.

    Serban B, Cretu B, Cursaru A, et al.

    EFORT open reviews 2023; (8(8)):606-614 doi:10.1530/EOR-23-0095.

    PMID: 37526250
  4. 4

    Local recurrence of soft-tissue sarcoma: issues in imaging surveillance strategy.

    Ezuddin NS, Pretell-Mazzini J, Yechieli RL, et al.

    Skeletal radiology 2018; (47(12)):1595-1606 doi:10.1007/s00256-018-2965-x.

    PMID: 29785452
  5. 5

    Beyond Clinical Examination: Utilizing MRI Surveillance to Detect Recurrence of Soft Tissue Sarcomas and Differentiate from Posttherapeutic Changes.

    Koenig FRM, Kielburg AH, Chaudhary SR, et al.

    Biomedicines 2024; (12(8)) doi:10.3390/biomedicines12081640.

    PMID: 39200105
  6. 6

    Can we use MRI to detect clinically silent recurrent soft-tissue sarcoma?

    Hirschmann A, van Praag VM, Haas RL, et al.

    European radiology 2020; (30(9)):4724-4733 doi:10.1007/s00330-020-06810-z.

    PMID: 32314057
  7. 7

    The value of re-staging chest CT at first local recurrence of extremity and trunk soft tissue sarcoma.

    Baig MS, Habib W, Attard V, et al.

    European radiology 2021; (31(4)):2377-2383 doi:10.1007/s00330-020-07366-8.

    PMID: 33037910
  8. 8

    Musculoskeletal Metastasis From Soft-tissue Sarcomas: A Review of the Literature.

    Pretell-Mazzini J, Seldon CS, D'Amato G, Subhawong TK

    The Journal of the American Academy of Orthopaedic Surgeons 2022; (30(11)):493-503 doi:10.5435/JAAOS-D-21-00944.

    PMID: 35320120
  9. 9

    PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

    Ryan CW, Merimsky O, Agulnik M, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(32)):3898-3905 doi:10.1200/JCO.2016.67.6684.

    PMID: 27621408
  10. 10

    The Combined Use of Inflammation Markers, Modified Glasgow Prognostic Score, and Sarculator Nomogram in Extremity Soft Tissue Sarcoma: A Multicenter Observational Study.

    Nakamura T, Takenaka S, Outani H, et al.

    Cancers 2024; (16(5)) doi:10.3390/cancers16051077.

    PMID: 38473433
  11. 11

    New Sarculator Prognostic Nomograms for Patients With Primary Retroperitoneal Sarcoma: Case Volume Does Matter.

    Callegaro D, Barretta F, Raut CP, et al.

    Annals of surgery 2024; (279(5)):857-865 doi:10.1097/SLA.0000000000006098.

    PMID: 37753660
  12. 12

    Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients.

    Voss RK, Callegaro D, Chiang YJ, et al.

    Annals of surgical oncology 2022; doi:10.1245/s10434-022-11442-2.

    PMID: 35224688
  13. 13

    Extremity Soft Tissue Sarcoma: A Multi-Institutional Validation of Prognostic Nomograms.

    Squires MH, Ethun CG, Donahue EE, et al.

    Annals of surgical oncology 2022; (29(5)):3291-3301 doi:10.1245/s10434-021-11205-5.

    PMID: 35015183
  14. 14

    Patient Perceptions of the Impact of Treatment (Surgery and Radiotherapy) for Soft Tissue Sarcoma.

    Hewitt L, Powell R, Zenginer K, et al.

    Sarcoma 2019; (2019()):9581781 doi:10.1155/2019/9581781.

    PMID: 31049021
  15. 15

    Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review.

    Assi T, Ngo C, Faron M, et al.

    Current treatment options in oncology 2023; (24(11)):1598-1613 doi:10.1007/s11864-023-01139-3.

    PMID: 37843627
  16. 16

    PATIENTS WITH SOFT TISSUE SARCOMA AFTER TREATMENT BY NON ORTHOPEDIC ONCOLOGIC SURGEONS: EPIDEMIOLOGICAL PROFILE, STAGING, AND THERAPEUTIC CHALLENGES.

    do Couto FB, Yonamine ES, Magno FG, et al.

    Acta ortopedica brasileira 2026; (34(1)):e293900 doi:10.1590/1413-785220263401e293900.

    PMID: 41696555

This page is for informational purposes only and does not replace professional medical advice. Always consult your oncology team regarding your specific soft tissue sarcoma surveillance schedule and risk factors.

Get notified when new evidence is published on Soft tissue sarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.